Early study paves way for new heart disease treatment
NCT ID NCT07677163
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage trial studies how different tablet forms of MK-1403, a drug designed for heart and blood vessel disease, are absorbed and tolerated in healthy adults. Researchers will measure the drug levels in the blood and monitor for any side effects. The results will help decide which formulation to use in future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-1403
What this could lead to
If successful, this study could help select the best formulation of MK-1403 for future trials in people with heart disease.
What could go wrong
This is a very early, small study in healthy people, not patients. The drug may not work as hoped in later trials or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.